Core Insights - Serina Therapeutics is presenting new data on its POZ-lipid technology at the 4th LNP Formulation & Process Development Summit, focusing on its potential to address challenges related to anti-PEG antibodies in mRNA vaccines [1][2] - The POZ-lipid demonstrated no IgM or IgG antibody response in rats, contrasting with PEG-lipid standards that elicited a strong antibody response, indicating a safer alternative for LNP formulations [2][3] - The absence of an immune response to POZ-lipid could lead to the development of safer and more effective gene therapy and RNA-based medicines, addressing concerns related to anaphylaxis and adverse events from PEGylated vaccines [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform™ for drug optimization [4] - The POZ Platform™ aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates [4]
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit